Clinical

Dataset Information

0

Randomized controlled trial to evaluate the prediction of the effectiveness for HLA-oriented therapy in gastric and colorectal cancer.


ABSTRACT: Interventions: HLA B40(+) HLA B51(+) PSK(-) PSK(+): PSK was administered orally from 14 days after gastrectomy at a dose of 3.0g/day and at least at a dose of over 270g. Per os fluoropyrimidine prodru (5-FU 150mg/day or UFT (300mg/day) was administered orally from 14 days after gastrectomy over 1 year. MMC was injected intravenously 0.4 mg/Kg intraoperatively and/or 0.2 mg/Kg on postoperative day 1. Primary outcome(s): Five year overall survival after gastrectomy Study Design: Parallel Randomized

DISEASE(S): Gastric Cancer Colorectal Cancer

PROVIDER: 2723206 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

Similar Datasets

| 2723211 | ecrin-mdr-crc
2010-07-29 | E-GEOD-22553 | biostudies-arrayexpress
2017-09-23 | GSE104086 | GEO
2017-09-23 | GSE104064 | GEO
2021-05-14 | GSE174386 | GEO
2023-01-09 | GSE193504 | GEO
2021-08-31 | GSE157127 | GEO
2020-06-04 | GSE151725 | GEO
2020-12-21 | GSE158713 | GEO
2019-04-19 | GSE121567 | GEO